

Clinical Studies

Pipeline overview — Phase 1/2 through Phase 4 studies

STUDIES INCLUDED

34

THERAPEUTIC AREAS

2

Interventional Phase 1/2–4 UCB programs across Neurology and Immunology, including the acquired Neurona cell-therapy asset, with status and phase reconciled to the ClinicalTrials.gov export (13 Jul 2026). Registries, Managed Access, Compassionate Use, Named Patient and Non-Interventional studies are excluded.

UCB studies at a glance

Therapeutic area	Phase 1/2	Phase 2	Phase 3	Phase 4	Total
Neurology	1	3	14	1	19
Immunology	–	3	12	–	15
Total	1	6	26	1	34

Studies are listed by phase on the following slides, grouped by therapeutic area. Phase 1/2 includes the acquired Neurona cell-therapy asset. Study status reflects the ClinicalTrials.gov Overall Status (13 Jul 2026).

UCB studies in Phase 1/2

Neurology · 1 study

Study code	Compound / brand	Indication(s)	Study status	References
rezanecel§	rezanecel	Drug-resistant unilateral mesial temporal lobe epilepsy (first-in-human)	Recruiting	NCT05135091 , UCB

§ rezanecel (NRTX-1001) acquired via Neurona Therapeutics (Apr 2026); investigational neuronal cell therapy. A second Phase 1/2 trial is also registered: NCT06422923 (bilateral mTLE).

UCB studies in Phase 2

6
STUDIES

Neurology · 4 studies

Study code	Compound / brand	Indication(s)	Study status	References
MG0006‡	Rystiggo	Generalized MG — paediatric, moderate to severe	Active, not recruiting	NCT06149559 , UCB
MG0014‡	Zilucoplan	Generalized MG — paediatric	Recruiting	NCT06055959 , UCB
TK0102	KYGEVVI	Thymidine kinase 2 (TK2) deficiency — open-label	Active, not recruiting	NCT03845712 , UCB

Immunology · 3 study

Study code	Compound / brand	Indication(s)	Study status	References
ATD002	Galvokimig	Atopic dermatitis — adults (dose-ranging)	Recruiting	NCT07277660 , UCB
COPD01	Galvokimig	Chronic obstructive pulmonary disease (COPD) — proof of concept	Not yet recruiting	NCT07725939 , UCB
NCFB01	Galvokimig	Non-cystic fibrosis bronchiectasis — adults (efficacy & safety, 24–52 weeks)	Not yet recruiting	NCT07720375 , UCB

‡ Registered on ClinicalTrials.gov as Phase 2/Phase 3.

UCB studies in Phase 3

Neurology · 14 studies

Study code	Compound / brand	Indication(s)	Study status	References
EP0156	BRIVIACT	Focal seizures — children & adolescents (safety/tolerability)	Recruiting	NCT04715646 , UCB
EP0224	BRIVIACT	Childhood / juvenile absence epilepsy — long-term safety	Active, not recruiting	NCT06315322 , UCB
N01269	BRIVIACT	Childhood / juvenile absence epilepsy — monotherapy efficacy, 2–25 y	Active, not recruiting	NCT04666610 , UCB
EP0213	Fintepla	Dravet syndrome — infants 1–<2 y (safety/PK)	Active, not recruiting	NCT06118255 , UCB
EP0216	Fintepla	CDKL5 deficiency disorder — pivotal efficacy	Active, not recruiting	NCT05064878 , UCB
EP0247†	Fintepla	Rett syndrome — ages 5–35 (double-blind vs placebo, then open-label)	Not yet recruiting	NCT07503444 , UCB
MG0008	Rystiggo	Generalized MG — paediatric (extension, 6-week cycles)	Enrolling by invitation	NCT06540144 , UCB
MG0038†	Rystiggo	Ocular MG — adults (pivotal)	Recruiting	NCT07463521 , UCB
MG0039†	Rystiggo	Ocular MG — adults (long-term extension)	Not yet recruiting	NCT07465289 , UCB
MOG001	Rystiggo	MOG antibody-associated disease (MOGAD) — adults	Active, not recruiting	NCT05063162 , UCB
EP0162	Staccato Alprazolam	Stereotypical prolonged seizures, ≥12 y — pivotal efficacy	Recruiting	NCT05077904 , UCB
EP0165	Staccato Alprazolam	Stereotypical prolonged seizures, ≥12 y — open-label safety extension	Enrolling by invitation	NCT05076617 , UCB
MG0011	Zilucoplan	Generalized MG — adults (open-label extension)	Active, not recruiting	NCT04225871 , UCB
MG0015	Zilucoplan	Generalized MG — paediatric (open-label extension)	Enrolling by invitation	NCT06435312 , UCB

UCB studies in Phase 3 (continued)

26
STUDIES

Immunology • 12 studies

Study code	Compound / brand	Indication(s)	Study status	References
AS0014	BIMZELX	Axial spondyloarthritis (AS & nr-axSpA) — open-label extension	Active, not recruiting	NCT04436640 , UCB
HS0005	BIMZELX	Hidradenitis suppurativa, mod–severe — open-label extension	Active, not recruiting	NCT04901195 , UCB
HS0006	BIMZELX	Hidradenitis suppurativa — paediatric (PK & safety)	Active, not recruiting	NCT06921850 , UCB
JA0005	BIMZELX	Juvenile idiopathic arthritis — ERA & juvenile PsA (PK & safety)	Recruiting	NCT06668181 , UCB
PA0012	BIMZELX	Active psoriatic arthritis — open-label extension	Completed	NCT04009499 , UCB
PA0016	BIMZELX	Active psoriatic arthritis — adults (head-to-head vs risankizumab)	Completed	NCT06624228 , UCB
PPP001	BIMZELX	Palmoplantar pustulosis — pivotal efficacy	Recruiting	NCT07219420 , UCB
PS0021	BIMZELX	Plaque psoriasis — 6–<18 y (head-to-head vs ustekinumab)	Recruiting	NCT06425549 , UCB
PS0039	BIMZELX	Plaque psoriasis, mod–severe — gene-expression biomarker study	Active, not recruiting	NCT06506916 , UCB
PS0007	CIMZIA	Plaque psoriasis — children, mod–severe (PK & efficacy)	Active, not recruiting	NCT04123795 , UCB
SL0044	Dapirolizumab pegol	Systemic lupus erythematosus — mod–severely active (pivotal)	Recruiting	NCT06617325 , UCB
SL0046	Dapirolizumab pegol	Systemic lupus erythematosus — long-term safety extension	Enrolling by invitation	NCT04976322 , UCB

UCB studies in Phase 4

Neurology · 1 study

Study code	Compound / brand	Indication(s)	Study status	References
MG0033	Rystiggo	Generalized MG — adults, China	Recruiting	NCT07246564 , UCB

Pipeline, Indication / Planned Timelines

H1 2026	H2 2026	2027	2028
 bimekizumab — BE BOLD Completed Psoriatic arthritis (H2H) Head-to-Head superiority demonstrated	 rozanolixizumab — Rystiggo Ongoing MOG-antibody disease Phase 3, Topline results in H2 2027 (event driven)	 STACCATO alprazolam Ongoing Stereotypical prolonged seizures Phase 3, Topline results in Q4 2026 / H1 2027 (event driven)	 dapirolizumab pegol* Ongoing Systemic lupus erythematosus 2nd confirmatory Phase 3 · Topline results in 2028
 fenfluramine — FINTEPLA Filed CDKL5 deficiency disorder	 galvokimig Initiated Non-CF bronchiectasis Phase 2 initiated in Q3 2026, Topline results in 2029	 bepranemab To start Alzheimer's disease Signal-confirming Phase 2 to start in H1 2027	 bimekizumab — Bimzelx Ongoing Palmoplantar pustulosis Phase 3, Topline results in 2029
 fenfluramine — FINTEPLA Initiated Rett syndrome Phase 3, Topline results in 2029	 galvokimig Initiated COPD Phase 2 initiated in Q3 2026, Topline results in 2029	 rezanecel To start MTLE Phase 3 to start in H1 2027	 galvokimig Ongoing Atopic dermatitis Phase 2b, Topline results (52-week data) in 2028
 rozanolixizumab — Rystiggo Initiated Ocular myasthenia gravis Phase 3, Topline results in 2029	 glovadalen Under evaluation Parkinson's disease Positive Phase 2a		
	 cizutamig To start MG and SARD-ILD Phase 2 planned to start end of 2026		



Inspired by patients.
Driven by science.

* In partnership with Biogen; 5-HT = 5-hydroxytryptamine or serotonin; AtD = Atopic dermatitis; CD40L = CD40 ligand; CDKL5 = cyclin-dependent kinase-like 5; COPD = Chronic Obstructive Pulmonary Disease; NCFB = Non-Cystic Fibrosis Bronchiectasis; FcRn = Neonatal Fragment Crystallizable Receptor; H = half-year; HS = hidradenitis suppurativa; IL = interleukin; JIA = Juvenile idiopathic arthritis; MG = myasthenia gravis; MTLE = mesial temporal lobe epilepsy; MOG = Myelin Oligodendrocyte Glycoprotein; PPP = palmoplantar pustulosis;; PSO = Psoriasis; SARD-ILD = systemic autoimmune rheumatic disease associated interstitial lung disease Projects not currently approved by any regulatory authority.